Skip to main content
SpringerLink
Log in

Tricuspid Valve Percutaneous Therapies

  • Interventional Cardiology (SR Bailey and T Helmy, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this review, we have focused on the currently available transcatheter tricuspid valve therapies, device selection, as well as role and management of tricuspid regurgitation (TR) in the setting of other transcatheter valvular procedures.

Recent Findings

In this review, we have enlisted the recently finished as well as ongoing trials in the percutaneous tricuspid valve therapies.

Summary

TR is highly prevalent yet remains underrecognized and is often untreated. TR has traditionally been managed conservatively with medical therapies including diuretics for volume management, whereas surgical therapies are reserved for those undergoing left-sided valvular surgery. Although the transcatheter devices for tricuspid repair and replacement are in clinical trials, the experience to date for their effectiveness and safety has been reassuring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. JACC Cardiovasc Imaging. 2019;12(3):433–42.

    Article  PubMed  Google Scholar 

  2. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6):897–902.

    Article  CAS  PubMed  Google Scholar 

  3. Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg. 2006;132(6):1258–61.

    Article  PubMed  Google Scholar 

  4. Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, et al. National Trends and Outcomes in Isolated Tricuspid Valve Surgery. J Am Coll Cardiol. 2017;70(24):2953–60.

    Article  PubMed  Google Scholar 

  5. Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of Referral of Patients With Severe Isolated Tricuspid Valve Regurgitation to Surgeons (from a French Nationwide Database). Am J Cardiol. 2018;122(2):323–6.

    Article  PubMed  Google Scholar 

  6. Dhoble A, Zhao Y, Vejpongsa P, Loghin C, Smalling RW, Estrera A, et al. National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery. J Cardiovasc Surg (Torino). 2019;60(1):119–27.

    Google Scholar 

  7. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43(3):405–9.

    Article  PubMed  Google Scholar 

  8. Bar N, Schwartz LA, Biner S, Aviram G, Ingbir M, Nachmany I, et al. Clinical Outcome of Isolated Tricuspid Regurgitation in Patients with Preserved Left Ventricular Ejection Fraction and Pulmonary Hypertension. J Am Soc Echocardiogr. 2018;31(1):34–41.

    Article  PubMed  Google Scholar 

  9. Wang N, Fulcher J, Abeysuriya N, McGrady M, Wilcox I, Celermajer D, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019;40(5):476–84.

    Article  CAS  PubMed  Google Scholar 

  10. Prihadi EA, Delgado V, Hahn RT, Leipsic J, Min JK, Bax JJ. Imaging Needs in Novel Transcatheter Tricuspid Valve Interventions. JACC Cardiovasc Imaging. 2018;11(5):736–54.

    Article  PubMed  Google Scholar 

  11. Hahn RT, Nabauer M, Zuber M, Nazif TM, Hausleiter J, Taramasso M, et al. Intraprocedural Imaging of Transcatheter Tricuspid Valve Interventions. JACC Cardiovasc Imaging. 2019;12(3):532–53.

    Article  PubMed  Google Scholar 

  12. Asmarats L, Puri R, Latib A, Navia JL, Rodes-Cabau J. Transcatheter Tricuspid Valve Interventions: Landscape, Challenges, and Future Directions. J Am Coll Cardiol. 2018;71(25):2935–56.

    Article  PubMed  Google Scholar 

  13. Paranon S, Acar P. Ebstein’s anomaly of the tricuspid valve: from fetus to adult: congenital heart disease. Heart. 2008;94(2):237–43.

    Article  PubMed  Google Scholar 

  14. Prihadi EA, Delgado V, Leon MB, Enriquez-Sarano M, Topilsky Y, Bax JJ. Morphologic Types of Tricuspid Regurgitation: Characteristics and Prognostic Implications. JACC Cardiovasc Imaging. 2019;12(3):491–9.

    Article  PubMed  Google Scholar 

  15. Adler DS. Non-functional tricuspid valve disease. Ann Cardiothorac Surg. 2017;6(3):204–13.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Al-Bawardy R, Krishnaswamy A, Bhargava M, Dunn J, Wazni O, Tuzcu EM, et al. Tricuspid regurgitation in patients with pacemakers and implantable cardiac defibrillators: a comprehensive review. Clin Cardiol. 2013;36(5):249–54.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER, et al. Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. Heart. 2014;100(12):960–8.

    Article  PubMed  Google Scholar 

  18. Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid Valve Dysfunction Following Pacemaker or Cardioverter-Defibrillator Implantation. J Am Coll Cardiol. 2017;69(18):2331–41.

    Article  PubMed  Google Scholar 

  19. Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation: a need to revise our understanding. J Am Coll Cardiol. 2015;65(21):2331–6.

    Article  PubMed  Google Scholar 

  20. Badano LP, Muraru D, Enriquez-Sarano M. Assessment of functional tricuspid regurgitation. Eur Heart J. 2013;34(25):1875–85.

    Article  PubMed  Google Scholar 

  21. Mangieri A, Montalto C, Pagnesi M, Jabbour RJ, Rodes-Cabau J, Moat N, et al. Mechanism and Implications of the Tricuspid Regurgitation: From the Pathophysiology to the Current and Future Therapeutic Options. Circ Cardiovasc Interv. 2017;10(7).

  22. Sagie A, Freitas N, Chen MH, Marshall JE, Weyman AE, Levine RA. Echocardiographic assessment of mitral stenosis and its associated valvular lesions in 205 patients and lack of association with mitral valve prolapse. J Am Soc Echocardiogr. 1997;10(2):141–8.

    Article  CAS  PubMed  Google Scholar 

  23. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J. 2017;38(45):3351–8.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Marciniak A, Glover K, Sharma R. Cohort profile: prevalence of valvular heart disease in community patients with suspected heart failure in UK. BMJ Open. 2017;7(1): e012240.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Benfari G, Antoine C, Miller WL, Thapa P, Topilsky Y, Rossi A, et al. Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction. Circulation. 2019;140(3):196–206.

    Article  CAS  PubMed  Google Scholar 

  26. Harada T, Obokata M, Omote K, Iwano H, Ikoma T, Okada K, et al. Functional Tricuspid Regurgitation and Right Atrial Remodeling in Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2021.

  27. Mascherbauer J, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Duca F, Dalos D, et al. Presence of isolated tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fraction. PLoS ONE. 2017;12(2): e0171542.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Ren QW, Li XL, Fang J, Chen Y, Wu MZ, Yu YJ, et al. The prevalence, predictors, and prognosis of tricuspid regurgitation in stage B and C heart failure with preserved ejection fraction. ESC Heart Fail. 2020.

  29. Zhou X, Otsuji Y, Yoshifuku S, Yuasa T, Zhang H, Takasaki K, et al. Impact of atrial fibrillation on tricuspid and mitral annular dilatation and valvular regurgitation. Circ J. 2002;66(10):913–6.

    Article  PubMed  Google Scholar 

  30. Abe Y, Akamatsu K, Ito K, Matsumura Y, Shimeno K, Naruko T, et al. Prevalence and Prognostic Significance of Functional Mitral and Tricuspid Regurgitation Despite Preserved Left Ventricular Ejection Fraction in Atrial Fibrillation Patients. Circ J. 2018;82(5):1451–8.

    Article  PubMed  Google Scholar 

  31. Messika-Zeitoun D, Thomson H, Bellamy M, Scott C, Tribouilloy C, Dearani J, et al. Medical and surgical outcome of tricuspid regurgitation caused by flail leaflets. J Thorac Cardiovasc Surg. 2004;128(2):296–302.

    Article  PubMed  Google Scholar 

  32. Lin G, Nishimura RA, Connolly HM, Dearani JA, Sundt TM 3rd, Hayes DL. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. J Am Coll Cardiol. 2005;45(10):1672–5.

    Article  PubMed  Google Scholar 

  33. Van De Heyning CM, Elbarasi E, Masiero S, Brambatti M, Ghazal S, Al-Maashani S, et al. Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. Can J Cardiol. 2019;35(4):389–95.

    Article  Google Scholar 

  34. Barbanti M, Binder RK, Dvir D, Tan J, Freeman M, Thompson CR, et al. Prevalence and impact of preoperative moderate/severe tricuspid regurgitation on patients undergoing transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2015;85(4):677–84.

    Article  PubMed  Google Scholar 

  35. Cremer PC, Wang TKM, Rodriguez LL, Lindman BR, Zhang Y, Zajarias A, et al. Incidence and Clinical Significance of Worsening Tricuspid Regurgitation Following Surgical or Transcatheter Aortic Valve Replacement: Analysis From the PARTNER IIA Trial. Circ Cardiovasc Interv. 2021;14(8): e010437.

    Article  CAS  PubMed  Google Scholar 

  36. Lindman BR, Maniar HS, Jaber WA, Lerakis S, Mack MJ, Suri RM, et al. Effect of tricuspid regurgitation and the right heart on survival after transcatheter aortic valve replacement: insights from the Placement of Aortic Transcatheter Valves II inoperable cohort. Circ Cardiovasc Interv. 2015;8(4).

  37. McCarthy FH, Vemulapalli S, Li Z, Thourani V, Matsouaka RA, Desai ND, et al. Association of Tricuspid Regurgitation With Transcatheter Aortic Valve Replacement Outcomes: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg. 2018;105(4):1121–8.

    Article  PubMed  Google Scholar 

  38. Fan J, Liu X, Yu L, Sun Y, Jaiswal S, Zhu Q, et al. Impact of tricuspid regurgitation and right ventricular dysfunction on outcomes after transcatheter aortic valve replacement: A systematic review and meta-analysis. Clin Cardiol. 2019;42(1):206–12.

    Article  PubMed  Google Scholar 

  39. Tomii D, Okuno T, Praz F, Heg D, Wild MG, Lanz J, et al. Potential Candidates for Transcatheter Tricuspid Valve Intervention After Transcatheter Aortic Valve Replacement: Predictors and Prognosis. JACC Cardiovasc Interv. 2021;14(20):2246–56.

    Article  PubMed  Google Scholar 

  40. Cohen SR, Sell JE, McIntosh CL, Clark RE. Tricuspid regurgitation in patients with acquired, chronic, pure mitral regurgitation. I. Prevalence, diagnosis, and comparison of preoperative clinical and hemodynamic features in patients with and without tricuspid regurgitation. J Thorac Cardiovasc Surg. 1987;94(4):481–7.

  41. Varadarajan P, Pai RG. Tricuspid regurgitation in patients with severe mitral regurgitation and normal left ventricular ejection fraction: risk factors and prognostic implications in a cohort of 895 patients. J Heart Valve Dis. 2010;19(4):412–9.

    PubMed  Google Scholar 

  42. Hahn RT, Asch F, Weissman NJ, Grayburn P, Kar S, Lim S, et al. Impact of Tricuspid Regurgitation on Clinical Outcomes: The COAPT Trial. J Am Coll Cardiol. 2020;76(11):1305–14.

    Article  CAS  PubMed  Google Scholar 

  43. Geyer M, Keller K, Bachmann K, Born S, Tamm AR, Ruf TF, et al. Concomitant tricuspid regurgitation severity and its secondary reduction determine long-term prognosis after transcatheter mitral valve edge-to-edge repair. Clin Res Cardiol. 2021;110(5):676–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kavsur R, Iliadis C, Spieker M, Brachtendorf BM, Tiyerili V, Metze C, et al. Predictors and prognostic relevance of tricuspid alterations in patients undergoing transcatheter edge-to-edge mitral valve repair. EuroIntervention. 2021;17(10):827–34.

    Article  PubMed  Google Scholar 

  45. Mehr M, Karam N, Taramasso M, Ouarrak T, Schneider S, Lurz P, et al. Combined Tricuspid and Mitral Versus Isolated Mitral Valve Repair for Severe MR and TR: An Analysis From the TriValve and TRAMI Registries. JACC Cardiovasc Interv. 2020;13(5):543–50.

    Article  PubMed  Google Scholar 

  46. Meijerink F, Koch KT, de Winter RJ, Robbers-Visser D, Boekholdt SM, Holierook M, et al. Tricuspid regurgitation after transcatheter mitral valve repair: Clinical course and impact on outcome. Catheter Cardiovasc Interv. 2021;98(3):E427–35.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Taramasso M, Alessandrini H, Latib A, Asami M, Attinger-Toller A, Biasco L, et al. Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry. JACC Cardiovasc Interv. 2019;12(2):155–65.

    Article  PubMed  Google Scholar 

  48. Braun D, Orban M, Orban M, Hagl C, Massberg S, Nabauer M, et al. Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation Using the Triple-Orifice Technique Versus the Bicuspidalization Technique. JACC Cardiovasc Interv. 2018;11(17):1790–2.

    Article  PubMed  Google Scholar 

  49. •• Lurz P, Stephan von Bardeleben R, Weber M, Sitges M, Sorajja P, Hausleiter J, et al. Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation. J Am Coll Cardiol. 2021;77(3):229–39. This study analyzing the transcatheter tricuspid valve repair using the TriClip device demonstrated safety and efficacy among the patients with moderate or greater TR. At the 1 year follow up TriClip was associated with continued clinical benefit and TR reduction at 1 year.

  50. Kodali S, Hahn RT, Eleid MF, Kipperman R, Smith R, Lim DS, et al. Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation. J Am Coll Cardiol. 2021;77(4):345–56.

    Article  PubMed  Google Scholar 

  51. Puri R, Rodes-Cabau J. The FORMA Repair System. Interv Cardiol Clin. 2018;7(1):47–55.

    PubMed  Google Scholar 

  52. Asmarats L, Perlman G, Praz F, Hensey M, Chrissoheris MP, Philippon F, et al. Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience. JACC Cardiovasc Interv. 2019;12(15):1438–47.

    Article  PubMed  Google Scholar 

  53. Planer D, Beeri R, Danenberg HD. First-in-Human Transcatheter Tricuspid Valve Repair: 30-Day Follow-Up Experience With the Mistral Device. JACC Cardiovasc Interv. 2020;13(18):2091–6.

    Article  PubMed  Google Scholar 

  54. Park YH, Chon MK, Lederman RJ, Sung SC, Je HG, Choo KS, et al. Mitral Loop Cerclage Annuloplasty for Secondary Mitral Regurgitation: First Human Results. JACC Cardiovasc Interv. 2017;10(6):597–610.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Min-Ku Chon S-MJ, Soo Yong Lee, Sang-Hyun Lee, Ki Won Hwang, Jeongsu Kim, Yong Hyun Park, Kook-Jin Chun, and June Hong Kim. TCT-18 Novel concept of catheter-based treatment for tricuspid regurgitation (Cerclage-TR block): a preliminary animal experiment in a swine model. J Am Coll Cardiol 2018 Sep, 72 (13_Supplement) B8. 2018.

  56. O'Connor S, editor Temporary Implantation of the CroiValve DUO Coaptation Valve in Patients with Massive and Torrential Tricuspid Regurgitation. TCT 2021; 2021; Miami, FL, USA.

  57. Nickenig G, Weber M, Schueler R, Hausleiter J, Nabauer M, von Bardeleben RS, et al. 6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation. J Am Coll Cardiol. 2019;73(15):1905–15.

    Article  PubMed  Google Scholar 

  58. • Nickenig G, Weber M, Schuler R, Hausleiter J, Nabauer M, von Bardeleben RS, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16(15):e1264–71. This study showed that the Cardioband Tricuspid valve repair system is efficacious with favorable results among the patients with symptomatic ≥ moderate TR. The reduction in annular dimensions as well as TR severity had remained significant at 2 years follow up along with improvement in the markers of quality of life.

  59. Rogers JH, Boyd WD, Bolling SF. Tricuspid annuloplasty with the Millipede ring. Prog Cardiovasc Dis. 2019;62(6):486–7.

    Article  PubMed  Google Scholar 

  60. Rogers T, Ratnayaka K, Sonmez M, Franson DN, Schenke WH, Mazal JR, et al. Transatrial intrapericardial tricuspid annuloplasty. JACC Cardiovasc Interv. 2015;8(3):483–91.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Kay JH, Maselli-Campagna G, Tsuji KK. Surgical Treatment of Tricuspid Insufficiency. Ann Surg. 1965;162:53–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Besler C, Meduri CU, Lurz P. Transcatheter Treatment of Functional Tricuspid Regurgitation Using the Trialign Device. Interv Cardiol. 2018;13(1):8–13.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Hahn RT, Meduri CU, Davidson CJ, Lim S, Nazif TM, Ricciardi MJ, et al. Early Feasibility Study of a Transcatheter Tricuspid Valve Annuloplasty: SCOUT Trial 30-Day Results. J Am Coll Cardiol. 2017;69(14):1795–806.

    Article  PubMed  Google Scholar 

  64. Hetzer R, Javier M, Delmo Walter EM. The Double-Orifice Valve Technique to Treat Tricuspid Valve Incompetence. J Heart Valve Dis. 2016;25(1):66–71.

    PubMed  Google Scholar 

  65. Khan JM, Rogers T, Schenke WH, Greenbaum AB, Babaliaros VC, Paone G, et al. Transcatheter pledget-assisted suture tricuspid annuloplasty (PASTA) to create a double-orifice valve. Catheter Cardiovasc Interv. 2018;92(3):E175–84.

    Article  PubMed  PubMed Central  Google Scholar 

  66. PCR E. STTAR: The Study of Transcatheter Tricuspid Annular Repair. In: Willard Hennemann P, editor. 2020. p. shorturl.at/wAXZ2.

  67. Kerner A, editor DaVingi™ Tricuspid Repair System Technology and Clinical Updates. TCT; 2018; San Diego.

  68. Latib A, Agricola E, Pozzoli A, Denti P, Taramasso M, Spagnolo P, et al. First-in-Man Implantation of a Tricuspid Annular Remodeling Device for Functional Tricuspid Regurgitation. JACC Cardiovasc Interv. 2015;8(13):e211–4.

    Article  PubMed  Google Scholar 

  69. Navia JL, Kapadia S, Elgharably H, Harb SC, Krishnaswamy A, Unai S, et al. First-in-Human Implantations of the NaviGate Bioprosthesis in a Severely Dilated Tricuspid Annulus and in a Failed Tricuspid Annuloplasty Ring. Circ Cardiovasc Interv. 2017;10(12).

  70. Navia JL, Kapadia S, Elgharably H, Maluenda G, Bartus K, Baeza C, et al. Transcatheter Tricuspid Valve Implantation of NaviGate Bioprosthesis in a Preclinical Model. JACC Basic Transl Sci. 2018;3(1):67–79.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Hahn R. NAVIGATE Transcatheter Tricuspid Valve Replacement… Early Findings – Technology and Clinical Updates. TCT San Diego. 2018.

  72. Hahn RT, George I, Kodali SK, Nazif T, Khalique OK, Akkoc D, et al. Early Single-Site Experience With Transcatheter Tricuspid Valve Replacement. JACC Cardiovasc Imaging. 2019;12(3):416–29.

    Article  PubMed  Google Scholar 

  73. Vaturi M, Vaknin-Assa H, Shapira Y, Perl L, Levi A, Koren A, et al. First-in-Human Percutaneous Transcatheter Tricuspid Valve Replacement With a Novel Valve. JACC Case Rep. 2021;3(10):1281–6.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Lu FL, Ma Y, An Z, Cai CL, Li BL, Song ZG, et al. First-in-Man Experience of Transcatheter Tricuspid Valve Replacement With LuX-Valve in High-Risk Tricuspid Regurgitation Patients. JACC Cardiovasc Interv. 2020;13(13):1614–6.

    Article  PubMed  Google Scholar 

  75. Sun Z, Li H, Zhang Z, Li Y, Zhang L, Xie Y, et al. Twelve-month outcomes of the LuX-Valve for transcatheter treatment of severe tricuspid regurgitation. EuroIntervention. 2021;17(10):818–26.

    Article  PubMed  Google Scholar 

  76. TriCares. TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System. 2021. p. https://www.tricares.com/assets/2021_Press_EN.pdf.

  77. Fam NP, von Bardeleben RS, Hensey M, Kodali SK, Smith RL, Hausleiter J, et al. Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System: A Multicenter, Observational. First-in-Human Experience JACC Cardiovasc Interv. 2021;14(5):501–11.

    Article  PubMed  Google Scholar 

  78. •• Kodali S, Hahn RT, George I, Davidson CJ, Narang A, Zahr F, Chadderdon S, Smith R, Grayburn PA, O'Neill WW, Wang DD, Herrmann H, Silvestry F, Elmariah S, Inglessis I, Passeri J, Lim DS, Salerno M, Makar M, Mack MJ, Leon MB, Makkar R; TRISCEND Investigators. Transfemoral Tricuspid Valve Replacement in Patients With Tricuspid Regurgitation: TRISCEND Study 30-Day Results. JACC Cardiovasc Interv. 2022 Mar 14;15(5):471–480. https://doi.org/10.1016/j.jcin.2022.01.016. PMID: 35272771. This is the early feasibility study for the Evoque system among the patients with clinically significant TR showing acceptable safety with significant TR reduction as well as quality-of-life improvement.

  79. Bapat V. The INTREPID Valve for Severe Tricuspid Regurgitation: Case Experience. CRT 2020.

  80. Laule M, Stangl V, Sanad W, Lembcke A, Baumann G, Stangl K. Percutaneous transfemoral management of severe secondary tricuspid regurgitation with Edwards Sapien XT bioprosthesis: first-in-man experience. J Am Coll Cardiol. 2013;61(18):1929–31.

    Article  PubMed  Google Scholar 

  81. Dreger H, Mattig I, Hewing B, Knebel F, Lauten A, Lembcke A, et al. Treatment of Severe TRIcuspid Regurgitation in Patients with Advanced Heart Failure with CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL): a randomised controlled trial. EuroIntervention. 2020;15(17):1506–13.

    Article  PubMed  Google Scholar 

  82. Lauten A, Ferrari M, Hekmat K, Pfeifer R, Dannberg G, Ragoschke-Schumm A, et al. Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation. Eur Heart J. 2011;32(10):1207–13.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Toggweiler S, De Boeck B, Brinkert M, Buhmann R, Bossard M, Kobza R, et al. First-in-man implantation of the Tricento transcatheter heart valve for the treatment of severe tricuspid regurgitation. EuroIntervention. 2018;14(7):758–61.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Knight Cardiovascular Institute, OHSU, Portland, OR, United States

    Bhaskar Bhardwaj, Joaquin E. Cigarroa & Firas Zahr

Authors
  1. Bhaskar Bhardwaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joaquin E. Cigarroa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Firas Zahr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Firas Zahr.

Ethics declarations

Conflict of Interest

Joaquin E. Cigarroa serves as a special government employee for the FDA Circulatory Devices Panel, which reviews PMA proposals for medical devices. Firas Zahr receives research and educational grants from Edwards Lifesciences and Medtronic. The other authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Interventional Cardiology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhardwaj, B., Cigarroa, J.E. & Zahr, F. Tricuspid Valve Percutaneous Therapies. Curr Cardiol Rep 24, 1209–1226 (2022). https://doi.org/10.1007/s11886-022-01739-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-022-01739-9

Keywords

Search

Navigation